Vascular Endothelial Growth Factor A

Gene

Related News

Sandoz Receives FDA Approval to Expand Enzeevu Label for Multiple Retinal Indications

Feb 18, 2026

The FDA has approved an expanded label for Sandoz's aflibercept biosimilar Enzeevu to include multiple retinal indications beyond its original approval for neovascular age-related macular degeneration. The product is expected to launch in the US in Q4 2026.

CStone Pharmaceuticals Receives FDA Clearance for CS2009 Phase II Trial in Solid Tumors

Feb 16, 2026

CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, in patients with advanced solid tumors across nine cancer indications.